You are viewing: Rest Of Europe Leukapheresis Market analysis
Part of: Leukapheresis Market (Global)

The Rest Of Europe Leukapheresis Market was valued at $1.2 Million in 2026 and projected to reach to $1.6 Million by 2031, representing a compound annual growth rate of 5.9%. Rest Of Europe's leukapheresis market demonstrates moderate growth potential as healthcare systems in smaller European nations invest in hematologic treatment capabilities.

Rest Of Europe Leukapheresis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Rest Of Europe Leukapheresis Market Trends and Insights

  • Rest Of Europe encompasses smaller healthcare markets with emerging adoption of leukapheresis technologies, driven by increasing prevalence of hematologic malignancies and growing awareness of cell therapy applications.
  • The region's growth trajectory reflects gradual healthcare infrastructure improvements and expanding access to advanced therapeutic apheresis procedures across non-major European economies. Rest Of Europe's leukapheresis market benefits from rising investment in oncology and immunotherapy treatments, though adoption rates remain lower than Western European counterparts.
  • Rest Of Europe continues to develop regulatory frameworks and clinical expertise to support leukapheresis adoption through 2031.
  • The market's moderate 5.9% CAGR indicates steady but measured expansion, with opportunities emerging from partnerships with established medical device manufacturers and increasing clinical trial activity in the region..

Key Market Statistics

  • CAGR (2026-2031) 5.9% CAGR
  • Market Size, 2026 ~USD 1.2 Million
  • Forecast, 2031 ~USD 1.6 Million
  • Country Rest Of Europe

Rest Of Europe Leukapheresis Market Overview

Market Size & Growth :

Rest Of Europe's leukapheresis market is valued at $1.2 million in 2026, expanding to $1.6 million by 2031 at a CAGR of 5.9%, reflecting steady adoption across smaller European healthcare systems.

Emerging Technology Adoption :

Smaller European markets are increasingly integrating leukapheresis technologies into clinical practice, driven by rising hematologic malignancy cases and growing recognition of cell therapy's therapeutic potential in the region.

Healthcare Infrastructure Development :

Rest Of Europe is experiencing gradual modernization of oncology and hematology departments, with improved access to advanced apheresis equipment and trained personnel supporting market expansion.

Awareness & Clinical Applications :

Increased medical education and clinical trials in Rest Of Europe are raising awareness of leukapheresis benefits for leukemia, lymphoma, and CAR-T cell therapy preparation, accelerating market penetration.

Rest Of Europe Leukapheresis Market Dynamics

  • The region benefits from knowledge transfer from larger European markets and increasing prevalence of blood cancers, creating demand for specialized apheresis procedures.
  • Growing partnerships between regional hospitals and international cell therapy providers are expected to drive adoption. By 2031, Rest Of Europe will likely see expanded leukapheresis utilization as reimbursement frameworks improve and clinical evidence strengthens.
  • Investment in training programs and equipment infrastructure will be critical to market development.
  • The region's growth trajectory, while slower than global averages, reflects the gradual but consistent integration of advanced hematologic technologies into emerging healthcare markets..

Related Ecosystem

Key Takeaways

  • Rest Of Europe's leukapheresis market is valued at $1.2 million in 2026 and will reach $1.6 million by 2031 at a 5.9% CAGR.
  • Rest Of Europe exhibits slower adoption compared to major European markets due to limited healthcare infrastructure and lower treatment awareness.
  • Rest Of Europe's growth is driven by increasing hematologic malignancy prevalence and expanding CAR-T cell therapy clinical programs.
  • Rest Of Europe presents untapped opportunities for market entrants through partnerships and regulatory pathway optimization.

Leukapheresis Market Report Scope

Report Metric Details
Base Year 2026
Fastest Growing Segment MULTIPLE MYELOMA (Indication)
Forecast Period 2026–2031
Growth Rate CAGR of 8.9% from 2026 to 2031
Largest Segment ACUTE LYMPHOCYTIC LEUKEMIA (Indication)
Market Size Base Year (Billions) ~USD 0.09 (2026)
Revenue Forecast (Billions) ~USD 0.14 (2031)
Segments Covered Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type

Rest Of Europe Leukapheresis Market Report Segmentation

7 segment dimensions are covered across the global market.

By Product Type

  • Devices
  • Disposables
  • Leukapheresis Devices
  • Leukapheresis Disposables

By Product Type 2024–2031

  • Collection Kits & Accessories
  • Filters & Membrane Consumables
  • Tubing Sets & Collection Bag

By Type

  • Australia
  • Belgium
  • Brazil
  • Canada
  • Centrifugal Devices
  • China
  • Diseased Leukopaks
  • France
  • Germany
  • India
  • Isolated Pbmcs
  • Italy
  • Japan
  • Kingdom Of Saudi Arabia (Ksa)
  • Membrane Separators
  • Mexico
  • Mobilized Leukopaks
  • Netherlands
  • New Zealand
  • Non-Mobilized Leukopaks
  • Poland
  • Rest Of Asia Pacific
  • Rest Of Europe
  • Rest Of GCC Countries
  • Rest Of Latin America
  • Rest Of Middle East & Africa
  • South Korea
  • Spain
  • Switzerland
  • Thailand
  • UK
  • United Arab Emirates (UAE)
  • US

By Application

  • Research Applications
  • Therapeutic Applications

By End User

  • Academic & Research Institutes
  • Blood Component Providers & Blood Centers
  • Contract Research Organizations
  • Hospitals & Transfusion Centers
  • Pharmaceutical & Biotechnology Companies

By Indication

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Hepatocellular Carcinoma
  • Multiple Myeloma
  • Non-Hodgkin’S Lymphoma
  • Other Indications
  • Pancreatic Cancer

By Leukopak Type

  • Diseased Leukopaks
  • Isolated Pbmcs
  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks

Target Audience

  • Medical Device Manufacturers : Evaluate market potential for leukapheresis equipment and apheresis systems in Rest Of Europe, identifying distribution channels and clinical adoption pathways for regional expansion.
  • Healthcare Providers & Hospital Networks : Assess demand for leukapheresis services and technology investments needed to enhance oncology/hematology capabilities and meet emerging patient treatment needs in their regions.
  • Cell Therapy & Biotech Companies : Understand leukapheresis infrastructure availability and clinical adoption rates in Rest Of Europe to plan CAR-T and cell therapy manufacturing partnerships and market development.
  • Healthcare Investors & Consultants : Analyze growth potential and investment opportunities in emerging European leukapheresis markets, supporting portfolio decisions and strategic advisory recommendations.
  • Regulatory & Market Access Professionals : Navigate region-specific regulatory requirements, reimbursement policies, and clinical practice standards affecting leukapheresis market entry and commercialization in Rest Of Europe.

Key Companies in the Rest Of Europe Leukapheresis Market

CompanyHQOwnershipStrongest segments
MAXCYTE, INCUnited StatesPublic CompanyExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees,

MAXCYTE, INC

MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.

Reasons to Buy this Report

  • Regional Market Segmentation : Gain detailed insights specific to Rest Of Europe's leukapheresis landscape, distinct from major European markets, enabling targeted market entry and localized strategy development.
  • Growth Opportunity Identification : Identify emerging opportunities in smaller European healthcare systems with 5.9% CAGR potential, capturing early-mover advantages before market saturation in developed regions.
  • Competitive Landscape Analysis : Understand competitive dynamics, key players, and market gaps specific to Rest Of Europe, informing product positioning and partnership strategies for regional expansion.
  • Investment & Expansion Planning : Support capital allocation decisions and market entry strategies with accurate forecasts through 2031, reducing investment risk in emerging European healthcare markets.
  • Regulatory & Reimbursement Insights : Access region-specific regulatory frameworks and reimbursement trends affecting leukapheresis adoption, critical for pricing strategy and market access planning in Rest Of Europe.

Frequently asked questions

What is the current market size of leukapheresis in Rest Of Europe?

Rest Of Europe's leukapheresis market is estimated at $1.2 million in 2026.

What is the projected market size for Rest Of Europe by 2031?

Rest Of Europe's leukapheresis market is forecast to reach $1.6 million by 2031.

What is the CAGR for Rest Of Europe's leukapheresis market?

Rest Of Europe's leukapheresis market is expected to grow at a compound annual growth rate of 5.9% from 2026 to 2031.

What factors are driving growth in Rest Of Europe's leukapheresis market?

Rest Of Europe's market growth is driven by increasing hematologic malignancy prevalence, expanding CAR-T cell therapy adoption, and improving healthcare infrastructure.

How does Rest Of Europe compare to other European regions?

Rest Of Europe exhibits slower adoption rates than Western Europe due to limited healthcare infrastructure, lower clinical awareness, and smaller patient populations.

RESEARCH METHODOLOGY

This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.

A breakdown of the primary respondents is provided below:

BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION

Leukapheresis Market
Size, and Share

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Leukapheresis Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.

Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics

Key Stakeholders

  • Apheresis device manufacturers and distributors
  • Leukapheresis product manufacturers and distributors
  • Leukopak manufacturers and distributors
  • Pharmaceutical and biotechnology companies
  • Healthcare service providers (including hospitals and transfusion centers)
  • Cancer treatment centers
  • Blood component providers & blood centers
  • Contract research organizations (CROS)
  • Academic and research institutes
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors

Report Objectives

  • To define, describe, segment, and forecast the leukapheresis market by type, application, end user, and region, and the leukopaks market, by type, indication, end user, and region
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukapheresis market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the leukapheresis market in five main regions (along with their respective key countries), namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the leukapheresis market and comprehensively analyze their core competencies and market share
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

Available customizations:

With the given market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
  • Company Information

Detailed analysis and profiling of additional market players (up to 5)

  • Geographic Analysis

Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries

Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries

  • Competitive Landscape Assessment

Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market

Competitive leadership mapping for established players in the US

 

Get the Full Leukapheresis Market Report

Full forecast, segment splits, and company analysis for all Leukapheresis Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status